24th August 2014
Human Longevity, Inc. signs agreement to develop and commercialise new stem cell therapies
Human Longevity Inc. (HLI) has signed an agreement with Celgene Cellular Therapeutics (CCT) to license, develop, and co-promote Celgene's proprietary placental cell population, PSC-100.
Human Longevity Inc. (HLI) was co-founded in March 2014 by Peter Diamandis, Craig Venter and Robert Hariri, with a specific purpose: extending the healthy, high performance human lifespan. This new company intends to achieve innovations in two main areas – genomics and stem cell sciences.
Over the next decade, HLI has the objective of sequencing the human genomes of 1 million individuals, while also collecting phenotypic, microbiome, imaging and metabalomic data. All of this information will be crunched using artificial intelligence and machine learning to provide extraordinary insights into human aging. In the arena of stem cells, they will begin harnessing stem cells as the regenerative engine of the body. Peter Diamandis has stated that it should be possible to extend healthy human life by 30-40 years if these treatments are successfully developed.
HLI has now made a significant step towards its eventual goals by signing an agreement with Celgene Cellular Therapeutics (CCT) to license, develop, and co-promote Celgene’s proprietary placental cell population, PSC-100. A variety of applications will be explored for this unique cell population – including for sarcopenia, an age-related condition resulting in degenerative loss of skeletal muscle mass, quality and strength. HLI will use its expertise and technology to model PSC-100 at the molecular level, complementing the data Celgene has gleaned from PSC-100 in Phase 1 human studies.
“We think that cellular-based therapeutics combined with our genomics-based discovery systems offer exciting potential for age-related diseases,” said Craig Venter, PhD, HLI CEO and co-founder. PSC-100 provides an “advanced basis” for testing cell therapy on diseases, he concluded.
HLI itself will be licensing access to its database, and developing new diagnostics and therapeutics as part of their product offerings.